BioCentury
BioCentury
YouTubeLinkedInXRSS
ARTICLE | Distillery Therapeutics

MECP2 overexpression disrupts neural progenitor cell fate programs

BC Staff
June 2, 2026 11:23 PM UTC

BCIQ Target Profiles

Methyl CpG binding protein 2 (MECP2) (RTT)

BCIQ Target Profiles

Methyl CpG binding protein 2 (MECP2) (RTT)

About BioCentury

Privacy & Legal

Contact

About BioCentury

Company Overview
Management
Editorial & Research
Scientific Advisory Board

Privacy & Legal

User Agreement
Terms of Use
Privacy Policy
Use of Images & Market Data
Reprints & Permissions

Contact

Contact Us
Advertising & Sponsorship
Customer Resource Center
Career Opportunities
Forgot Password
YouTubeLinkedInXRSS
BioCentury
© 2026 BioCentury Inc. All Rights Reserved.
Copyright © 2026 BioCentury Inc. All Rights Reserved.
YouTubeLinkedInXRSS